FOLH1 and cancer: Due to the limitations of the principle of 99mTc-MDP uptake, bone scanning cannot detect bone metastases at this stage, while 18F-DCFPyL, by specifically binding with PSMA on cancer cells, can detect these early metastatic lesions, which provides a significant advantage in their discovery (18).